X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

By Gabby Migliara  |    November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...   Read More

Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015

By Gabby Migliara  |    October 21, 2020
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recent study published in Health Affairs. This underscores the crucial role...   Read More

Survey found insurance premiums grew faster than inflation in 2020

By Gabby Migliara  |    October 20, 2020
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than both the rate...   Read More

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...   Read More

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

By Gabby Migliara  |    August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...   Read More

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

By Gabby Migliara  |    August 12, 2020
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...   Read More

Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines

By Gabby Migliara  |    August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...   Read More

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

By Katie Koziara  |    August 5, 2020
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights...   Read More

New data show commercially insured patients face increasingly high cost sharing for brand medicines

By Gabby Migliara  |    July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...   Read More

Payers subject 80% of new RA and MS patients to utilization management restrictions

By Gabby Migliara  |    July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates